Effects of Immunocytokine Combined with Cattle Encephalon Glycoside and Ignotin on CTGF, HO-1 and NT-3 in Patients with Type 2 Diabetic Peripheral Neuropathy
AbstractBackground: This study was designed to explore the correlation of connective tissue growth factor (CTGF), heme oxygenase (HO-1), neurotrophic factors (NT-3) with type 2 diabetic peripheral neuropathy, as well as the changes after immune cytokine alone and combined with cattleencephalon glycoside and ignotin treatment.Methods: Seventy-six patients with type 2 diabetes and peripheral neuropathy charged into People’s Hospital of Rizhaolanshan, China from 2014-2016 were selected. The severity of neuropathy was evaluated by TCSS. Pearson analysis was used to analyze the correlation between the degree of neuropathy and CTGF, HO-1 and NT-3. The patients were randomly divided into control group and observation group, n=38. The control group accepted TGF-β1 treatment on the basis of controlling diet and blood sugar, while the observation group was treated with cattle encephalon glycoside and ignotin injection on the basis of control group. CTGF、HO-1, NT-3 concentration in the blood and nerve conductive velocity (NCV) were detected and analyzed before and after treatment.Results: CTGF(r=-0.865), HO-1(r=-0.706), NT-3(r=-0.587) was negatively correlated with TCSS scores. After treatment, the concentrations of CTGF、HO-1and NT-3 in the observation group were higher than the control group (P<0.05). In moderate and severe lesions, the concentrations of CTGF, HO-1and NT-3 in the observation group were higher than the control group (P<0.05). The conduction velocity of nerve increased with the increase of CTGF, HO-1 and NT-3 concentrations. The obvious effective rate and total effective rate of observation group were both higher than the control group.Conclusion: Immune cytokine TGF-β1 combined with cattle encephalon glycoside and ignotin injection could improve the contents of CTGF, HO-1 and NT-3, and be better to treat the peripheral neuropathy of type 2 diabetes.
Vinik AI, Nevoret ML, Casellini C, Parson H (2013). Diabetic neuropathy. Endocrinol Metab Clin North Am, 42: 747-787.
Yoo M, D'Silva LJ, Martin K, Sharma NK, Pasnoor M, LeMaster JW, Kluding PM (2015). Pilot Study of Exercise Therapy on Painful Diabetic Peripheral Neuropa-thy. Pain Med, 16: 1482-1489.
Mitro N, Cermenati G, Brioschi E et al (2014). Neuroactive steroid treatment modulates myelin lipid profile in diabetic peripheral neuropathy. J Steroid Biochem Mol Biol, 143: 115-121.
Davidson EP, Coppey LJ, Kardon RH, Yorek MA (2014). Differences and simi-larities in development of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic rats. Invest Ophthalmol Vis Sci, 55: 1222-1230.
Jin HY, Lee KA, Park TS (2016). The impact of glycemic variability on diabetic periph-eral neuropathy. Endocrine, 53: 643-648.
Jernigan SD, Pohl PS, Mahnken JD, Klud-ing PM (2012). Diagnostic accuracy of fall risk assessment tools in people with dia-betic peripheral neuropathy. Phys Ther, 92: 1461-1470.
Kordi YA, Shadmehr A, Olyaei G, Talebian S, Bagheri H (2014). The effectiveness of a single session of Whole-Body Vibration in improving the balance and the strength in type 2 diabetic patients with mild to moderate degree of peripheral neuropathy: A pilot study. J Bodyw Mov Ther, 18: 82-86.
Nie C, Bao HP (2012). Analysis of the relat-ed risk factors of diabetic peripheral neu-ropathy. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 26: 467-469.
Meo SA, Rouq FA, Suraya F, Zaidi SZ (2016). Association of ABO and Rh blood groups with type 2 diabetes melli-tus. Eur Rev Med Pharmacol Sci, 20: 237-242.
Evliyaoglu F, Karadag R, Burakgazi AZ (2012). Ocular neuropathy in peripheral neuropathies. Muscle Nerve, 46: 681-686.
Deng H, Yin J, Zhang J, Xu Q, Liu X, Liu L, Wu Z, Ji A (2014). Meta-analysis of methylcobalamin alone and in combina-tion with prostaglandin E1 in the treat-ment of diabetic peripheral neuropathy. Endocrine, 46: 445-454.
Abrigo J, Morales MG, Simon F, Cabrera D, Di Capua G, Cabello-Verrugio C (2015). Apocynin inhibits the upregulation of TGF-beta1 expression and ROS produc-tion induced by TGF-beta in skeletal muscle cells. Phytomedicine, 22: 885-893.
Caraci F, Gulisano W, Guida CA, Impelliz-zeri AA, Drago F, Puzzo D, Palmeri A (2015). A key role for TGF-beta1 in hip-pocampal synaptic plasticity and memory. Sci Rep, 5: 11252.
Ercan E, Han JM, Di Nardo A, Winden K, Han MJ, Hoyo L, Saffari A, Leask A, Geschwind DH, Sahin M (2017). Neu-ronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuber-ous sclerosis complex. J Exp Med, 214: 681-697.
Aung KH, Win-Shwe TT, Kanaya M, Taka-no H, Tsukahara S (2014). Involvement of hemeoxygenase-1 in di(2-ethylhexyl) phthalate (DEHP)-induced apoptosis of Neuro-2a cells. J Toxicol Sci, 39: 217-229.
Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, Chen L, Braganza C, Montgomery C, Mendell JR (2014). AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther, 22: 511-521.
Kennedy AJ, Wellmer A, Facer P, Saldanha G, Kopelman P, Lindsay RM, Anand P (1998). Neurotrophin-3 is increased in skin in human diabetic neuropathy. J Neurol Neurosurg Psychiatry, 65: 393-395.
Gao Y, Hu YZ, Li RS, Han ZT, Geng Y, Xia Z, Du WJ, Liu LX, Zhang HH, Wang LN (2015). Cattle encephalon gly-coside and ignotin injection improves cognitive impairment in APPswe/PS1dE9 mice used as multitar-get anti-Alzheimer's drug candidates. Neuropsychiatr Dis Treat, 11: 537-548.
Song Y, Yao S, Liu Y, Long L, Yang H, Li Q, Liang J, Li X, Lu Y, Zhu H, Zhang N (2017). Expression levels of TGF-beta1 and CTGF are associated with the severi-ty of Duchenne muscular dystrophy. Exp Ther Med, 13: 1209-1214.
Ermis N, Gullu H, Caliskan M, Unsal A, Kulaksizoglu M, Muderrisoglu H (2010). Gabapentin therapy improves heart rate variability in diabetic patients with periph-eral neuropathy. J Diabetes Complications, 24: 229-233.